Abstracts tagged "Biologic agents"

Abstract Number: 804 • 2013 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibitors and The Risk Of Acute Coronary Syndrome In Rheumatoid Arthritis – a National Cohort Study
Lotta Ljung^1,2, Johan Askling³, Solbritt M. Rantapää-Dahlqvist⁴, Lennart T.H. Jacobsson⁵ and The ARTIS Study Group⁶, ¹Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The high risk of ischemic heart disease (IHD) in patients with rheumatoid arthritis (RA) has been linked to inflammation and disease severity. Treatment with…
Abstract Number: 2337 • 2013 ACR/ARHP Annual Meeting
Serious Adverse Events Associated With Using Biological Agents To Treat Rheumatic Diseases: Network Meta-Analysis From a National Guideline Panel
Simon Tarp¹, Ulrik Tarp², Lis S. Andersen³, Tove Lorenzen⁴, Hanne M. Lindegaard⁵, Michael Stoltenberg⁶, Hanne S. Jensen⁷, Birgitte Brock⁸, Camilla M. Mikkelsen⁹, Dorte V. Jensen¹⁰, Karsten Asmussen⁷, Troels Herlin¹¹ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Rheumatology, Copenhagen University Hospital, Gentofte, Denmark, ⁴Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Copenhagen University Hospital, Køge, Denmark, ⁷Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ⁸Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark, ⁹The Capital Region of Denmark Hospital Pharmacy, Medicine Information Centre, Copenhagen NV, Denmark, ¹⁰The Danish Rheumatologic Database (DANBIO), Center of Rheumatology and Spine Diseases VRR, Copenhagen University Hospital, Glostrup, Denmark, ¹¹Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Clinical guidelines are needed to help clinicians provide optimal medical treatment and advise patients about the potential hazards associated with certain drugs. Our objective…
Abstract Number: 1459 • 2013 ACR/ARHP Annual Meeting
Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis
Kensuke Koyama¹, Katsunori Ikari¹, Atsuo Taniguchi², Shigeki Momohara² and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: There is some rheumatoid arthritis (RA) patients with poor responses to certain biologics which requires switching to another biologics. However, there is no solid…
Abstract Number: 805 • 2013 ACR/ARHP Annual Meeting
Good Response On Tumour Necrosis Factor Inhibitors Are Associated With a Decreased Risk Of Acute Coronary Syndromes In Patients With Rheumatoid Arthritis
Lotta Ljung^1,2, Lennart T.H. Jacobsson³, Solbritt M. Rantapää-Dahlqvist⁴, Johan Askling⁵ and The ARTIS Study Group⁶, ¹Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁴Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Inflammatory activity, as well as traditional cardiovascular risk factors, have been suggested to underlie the increased risk of coronary disease in patients with rheumatoid…
Abstract Number: 2319 • 2013 ACR/ARHP Annual Meeting
Comparative Safety Of Biological Agents Among Medicare Rheumatoid Arthritis Patients
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸, Paul M. Muntner¹ and Jeffrey R. Curtis³, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several new biologic disease-modifying antirheumatic drugs (DMARDs) have been approved for treatment of rheumatoid arthritis (RA) in United States. However, their comparative risks of…
Abstract Number: 1468 • 2013 ACR/ARHP Annual Meeting
Reasons For Discontinuation Of Biologic Agents In Rheumatoid Arthritis Patients
Eric Elkin¹, Martin J. Bergman², Tripthi Kamath³, Sarika Ogale³, Adam Turpcu³, Kristin King⁴, Jae Oh⁴, Monarch Shah¹ and Max I. Hamburger⁵, ¹ICON Clinical Research, San Francisco, CA, ²Taylor Hospital, Ridley Park, PA, ³Genentech, South San Francisco, CA, ⁴ICON Late Phase and Outcomes Research, San Francisco, CA, ⁵Rheumatology Associates, Melville, NY
Background/Purpose: Results from randomized controlled trials indicate that about one-third of rheumatoid arthritis (RA) patients initially treated with anti-TNF agents do not respond, show a…
Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting
Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study
Zaki AbouZahr¹, Andrew Spiegelman², Maria Cantu³ and Bernard Ng⁴, ¹Baylor College of Medicine, Houston, TX, ²Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, ³Baylor College Of Medicine, Houston, TX, ⁴Michael E. DeBakey VA Medical Center, Houston, TX
Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
Abstract Number: 2326 • 2013 ACR/ARHP Annual Meeting
Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study
Michael E. Weinblatt¹, Michael H Schiff², Robert Valente³, Désirée M. van der Heijde⁴, Gustavo Citera⁵, Ayanbola Elegbe⁶, Michael A Maldonado⁶ and Roy Fleischmann⁷, ¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Denver, CO, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) is the first 2 year, active comparator study in RA patients utilizing…
Abstract Number: 1476 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study
Arthur N. Lau¹, Alpesh Shah², Melissa Deamude³, Cynthia Mech⁴, Robert Bensen⁵ and William G. Bensen⁶, ¹Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, ³Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ⁴Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: Biological drugs have dramatically improved the prognosis of rheumatoid arthritis (RA), especially in those with early disease. These patientsare often in younger age with fewer…
Abstract Number: 481 • 2013 ACR/ARHP Annual Meeting
Down-Titration of Biological Therapies In Rheumatoid Arthritis In Daily Clinical Practice
Miguel Arredondo¹, Iciar Cañamares², Esther Ramírez-Herráiz², Isidoro Gonzalez-Alvaro³, Alberto Garcia-Vadillo³, Alberto Morell¹, Rosario Garcia-Vicuña⁴ and Jose María Alvaro-Gracia⁵, ¹Unidad de Terapias Biológicas, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Servicio de Farmacia, Hospital Universitario de La Princesa, Madrid, Spain, ³Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁵Unidad de Terapias Biológicas. Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: One of the limiting factors for the use of biological therapies (BT) is cost. For this reason, the development of cost optimization strategies without…
Abstract Number: 2208 • 2013 ACR/ARHP Annual Meeting
Psychological Condition Of JIA Patients Treated With Biologic Agents. – A Nation-Wide Survey In Japan
Yuki Osako¹, Yukiko Nonaka², Harumi Akaike², Tomohiro Kubota³, Tsuyoshi Yamatou², Tomokazu Nagakura⁴, Junko Yasumura⁵, Hiroyuki Imanaka² and Syuji Takei⁶, ¹School of Health Sciences, Faculty of Medicine,Department of Maternal & Child Nursing and Midwifery, Kagoshima University, Kagoshima city, Japan, ²Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ³Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁴Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁵Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
Background/Purpose: Biologic agents, newly developed medications targeting for inflammatory cytokines such as TNF-alpha or IL-6, have been drastically improving the disease course of JIA who…
Abstract Number: 1439 • 2013 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis
Charles Inderjeeth¹, Andrew Redfern¹, Michael Huang², Yun Hardiman², Theresa Grant², Lawrence C. Fritz², David Fuller³, David Haughey⁴ and Mark C. Totoritis², ¹Linear Clinical Research Ltd, Perth, Australia, ²Santarus, Inc., San Diego, CA, ³INC Research, Inc., New South Wales, Australia, ⁴ICON Development Solutions, Whitesboro, NY
Background/Purpose: Very late antigen-1 (VLA-1; α1β1 integrin), a cell adhesion molecule expressed on activated lymphocytes and monocytes/macrophages, binds extracellular matrix molecules and facilitates migration, proliferation,…
Abstract Number: 484 • 2013 ACR/ARHP Annual Meeting
Response To Biologic Disease-Modifying Anti-Rheumatic Drugs After Discontinuation Of Anti-Tumor Necrosis Factor Alpha Agents In Rheumatoid Arthritis Patients
Eric Elkin¹, Max I. Hamburger², Tripthi Kamath³, Sarika Ogale³, Adam Turpcu³, Jae Oh⁴, Kristin King⁴, Monarch Shah¹ and Martin J. Bergman⁵, ¹ICON Clinical Research, San Francisco, CA, ²Rheumatology Associates, Melville, NY, ³Genentech, South San Francisco, CA, ⁴ICON Late Phase and Outcomes Research, San Francisco, CA, ⁵Taylor Hospital, Ridley Park, PA
Background/Purpose: Rheumatoid arthritis (RA) patients who have failed an anti-TNF agent as their first biologic agent have the option of switching to a second aTNF…
Abstract Number: 2165 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologic Agents In Patients With Poly-Articular Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Controlled Withdrawal Trials
Gil Amarilyo¹, Simon Tarp², Ivan Foeldvari³, Neta Cohen⁴, Tracy D. Pope⁵, Jennifer M.P. Woo⁶, Robin Christensen² and Daniel Furst⁵, ¹Dana-Dwek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ³Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁴Dana-Duek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵David Geffen School of Medicine, University of California, Los Angeles, CA, ⁶Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Although various biologic agents (BAs) are in use for polyarticular juvenile idiopathic arthritis (pJIA), a combined meta-analytic summary comparing the efficacy and safety among…
Abstract Number: 1444 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Induced By Tumor Necrosis Factor Antagonists In Chronic Inflammatory Arthropathies: Retrospective Study In Clinical Practice Conditions
Jose Inciarte-Mundo¹, Maria Victoria Hernández², Sonia Cabrera¹, Virginia Ruiz-Esquide³, Julio Ramirez¹, Juan D. Cañete², Jordi Yague⁴ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic, Barcelona, Spain, ⁴Hospital Clínic / IDIBAPS, Barcelona, Spain
Background/Purpose: Biological therapy has proved efficacious in various chronic inflammatory arthropathies but, in practice, clinical efficacy is reduced in some patients, suggesting drug-induced immunogenicity as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].